SUPN Q4 2021 Earnings — Supernus Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

SUPNSupernus Pharmaceuticals, Inc.

$3B

Q4 2021 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$159M+10.8% YoY

Gross Profit

$142M89.3% margin

Operating Income

$6M3.8% margin

Net Income

$2M1.5% margin

EPS (Diluted)

$0.04

QoQ Revenue Growth

+7.1%

Cash Flow

Operating Cash Flow

$49M

Free Cash Flow

$49M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$1.7B

Total Liabilities

$873M

Stockholders' Equity

$816M

Cash & Equivalents

$203M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$159M	$144M	+10.8%
Gross Profit	$142M	$125M	+13.6%
Operating Income	$6M	$43M	-85.8%
Net Income	$2M	$31M	-92.1%

Revenue Segments

Product

$155M51%

Trokendi Xr

$73M24%

Oxtellar X R

$29M9%

APOKYN

$26M9%

Qelbree

$7M2%

MYOBLOC

$6M2%

Royalty

$4M1%

XADAGO

$4M1%